The failure of Circassia’s cat allergy vaccine product in a Phase III study, and other recent setbacks including a one-year delay to Allergy Therapeutics’ US ambitions, have not stymied the excitement in a sector that promises new approaches to grass, tree, peanut and other food allergies, and much more convenient treatment regimens.
The allergy vaccine sector is in good shape, with companies investing in and testing new approaches, some consolidation among allergy-focused firms, and a desire among companies to “go global” and to break out of their European strongholds, says Manuel Llobet, CEO of Allergy Therapeutics PLC, a rapidly growing UK-based allergy company.
The sector may have been stunned by the recent failure of Circassia Pharmaceuticals PLC’s investigational cat allergy product, Cat-SPIRE,...
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
